Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Urol Oncol. 2021 Feb 7;39(5):301.e17–301.e28. doi: 10.1016/j.urolonc.2021.01.021

Table 4:

Summary of pairwise agreement between 3 laboratories (n=576): Kappa estimate (95% confidence interval)*

Marker Lab B and Lab A Lab B and Lab C Lab A and Lab C
p53 68%
(61%, 75%)		   78%
(71%, 85%)		   59%
(51%, 67%)
p21 29%
(23%, 36%)		 40%
(31%, 49%)		 53%
(45%, 60%)
p16 72%
(66%, 79%)		 75%
(68%, 81%)		 90%
(85%, 94%)
Rb 41%
(34%, 49%)		 25%
(19%, 31%)		 67%
(61%, 74%)
E-cadherin 36%
(27%, 44%)		 52%
(38%, 65%)		 31%
(23%, 39%)
Cylin D1 55%
(40%, 70%)		 63%
(48%, 79%)		 65%
(53%, 77%)
EGFR 33%
(26%, 39%)		 17%
(12%, 22%)		 54%
(45%, 64%)
Her-2 35%
(25%, 46%)		 51%
(39%, 64%)		 66%
(57%, 75%)
VEGF 1.40%
(−1%, 4%)		 - -
*

A value of 100% indicates perfect agreement and a value of 0% indicates a random relationship